BioNTech Snaps Up Pancreatic Cancer Antibody, US Infrastructure

Europe’s largest private family-backed biotech adds to its antibody pipeline and its infrastructure in the US with assets from MabVax Therapeutics, in order to pioneer patient-specific immunotherapies for cancer and infections.  

Pancreas
Pancreatic cancer is crying out for new approaches to therapy. • Source: Shutterstock

Europe’s largest privately held biotech, BioNTech SE, is adding to its clinical-stage product pipeline through the acquisition of antibody assets and US infrastructure from San Diego, CA-based MabVax Therapeutics Holdings Inc., in an agreement announced on 9 May. The acquisition will include the antibody, MVT-5873, in Phase I in patients with pancreatic cancer, and preclinical antibodies.

The Strüngmann family-backed BioNTech has more than 1,000 employees in Mainz and other sites in Germany, and the infrastructure acquired...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

 

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.

More from Business

J&J Delivers In Q2 Despite Stelara Drop, Raising Guidance

 

Stelara revenues declined 42.7% in the quarter due to biosimilars, but innovative medicines grew 4.9%, surpassing $15bn for the quarter. Although pharma tariffs could be coming, the firm said the impact continues to be hard to predict.

PureTech Ponders Way Forward As CEO Exits

 
• By 

Bharatt Chowrira departs days after firm’s chair stepped down.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?